Cat# : THP-0211
|THP-0211||Pegdinetanib||June 05, 2023||1 vial||$3,998.00||
|Add to Cart Online Order Request a Bulk Order|
|Description:||CT-322 is a proprietary Adnectin(TM) protein therapeutic that specifically binds to VEGFR-2, which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.|
|Molecular Weight:||Not Available|
|Purity:||>99% by SDS-Page and HPLC analysis|
|Endotoxin Level:||<0.001 EU per 1 μg of the peptide by the LAL method|
|Applications:||Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.|
|Examples of Clinical Use:||Cancer/tumors (unspecified) and macular degeneration|
|Mechanism of action:||CT-322 specifically inhibits VEGFR-2 activation by its ligands VEGF-A, VEGF-C, and VEGF-D. In preclinical studies, this cell-surface receptor drives angiogenesis (growth of new blood vessels) in solid tumors, and CT-322 inhibits the tumorgenic effect of VEGFR-2 in preclinical models. CT-322 was designed using the PROfusion(TM) System, Adnexus' patented product design engine.|
|Affected organisms:||Not Available|
|Targets:||Target 1. Vascular endothelial growth factor receptor 2|
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.